FDA Broadens Its Consumer Safety Alert to Cover All Unapproved GLP-1 Weight-Loss Drugs, With New Telehealth Red Flags

The FDA has revised and broadened the consumer safety communication it uses to warn the public about weight-loss drugs sold outside the approved supply chain. The page, titled 'FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss' and marked current as of September 1, 2026, now covers the whole GLP-1 class rather than semaglutide alone, and the agency's older semaglutide-specific safety page redirects to it. The update lands as compounded and counterfeit GLP-1 products continue to move through telehealth channels, and it spells out, in unusually specific terms, the warning signs the FDA wants patients to watch for online.

What the FDA changed

The agency's long-standing patient page on medications containing semaglutide now points to a single, broader statement about unapproved GLP-1 drugs used for weight loss. The practical effect is a consolidation: instead of a semaglutide-only alert, the FDA is addressing the full class of GLP-1 receptor agonists marketed for weight loss, including tirzepatide, and framing the risks around any version that has not gone through FDA approval. The document is dated current as of September 1, 2026.

The core message is that unapproved products, including many compounded ones, 'do not undergo FDA's review for safety, effectiveness and quality before they are marketed.' Approval is the step that verifies a drug's ingredients, dosing and manufacturing, and the FDA's position is that products skipping it carry risks the agency has not evaluated.

The safety concerns the FDA lists

The statement groups its concerns into a few concrete categories rather than a general caution:

• Different active ingredients: the FDA says salt forms 'including semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs,' and that peptides such as retatrutide and cagrilintide cannot legally be used in compounding.
• Dosing errors: the agency says it received 'multiple reports of adverse events, some requiring hospitalization,' tied to dosing mistakes with compounded semaglutide, an issue that arises when patients draw doses from multi-dose vials.
• Contamination and storage: the FDA recommends discarding a multi-dose vial within 28 days after first use, and not using an injectable GLP-1 drug that 'arrives warm or with insufficient refrigeration, as this can affect the drug's quality.'
• Counterfeits: the agency warns that counterfeit Ozempic could contain 'the wrong ingredients' or 'too little, too much or no active ingredient at all.'

On the scale of the problem, the FDA put numbers on its adverse event tracking. As of May 31, 2026, the agency said it had received roughly 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide. Adverse event reports are voluntary signals, not proof that a specific product caused a specific harm, but the FDA treats a rising count as a reason to caution the public.

The telehealth red flags, in the FDA's words

The most notable part of the update for the online-care market is a checklist of seller behaviors the FDA tells consumers to avoid. According to the statement, patients should be wary of companies that:

• Claim a compounded drug is equivalent to the FDA-approved version.
• Offer deep discounts or prices that seem too good to be true.
• Send products that are differently packaged or that arrive damaged.
• Dispense without requiring a licensed doctor to screen the patient first.
• Are unreachable when the patient has questions after the purchase.

None of these behaviors is unique to any one platform, and the FDA does not name companies in the consumer statement. The list functions as a general set of buyer-beware signals for anyone obtaining GLP-1 medication through a website or app.

The counterfeit Ozempic thread

Alongside compounding, the FDA continues to flag counterfeits entering the legitimate supply chain. In a separate but related alert, most recently updated on December 5, 2025, the agency said it had obtained 'dozens of units of counterfeit Ozempic (semaglutide) injection 1 mg' distributed illegally outside the authorized channel. The FDA said the counterfeit units carried lot number PAR1229 (which is also a genuine lot number) and could be told apart by the placement of the EXP and LOT text on the pen label. The agency said testing of the seized products was underway.

The counterfeit and compounding issues are distinct: a counterfeit is a fake made to look like an approved brand, while a compounded drug is prepared by a pharmacy. The FDA's broader point is that both sit outside the approval process that verifies what is actually in the vial.

What this means, and what it does not

A consumer safety communication is education and guidance. It does not, by itself, change what is legal to prescribe, compound or sell. Whether compounding of semaglutide and tirzepatide is permitted turns on the drug shortage status and on litigation and rulemaking, not on this page. A federal appeals court recently affirmed the FDA's decisions ending the GLP-1 shortages, which underpin limits on large-scale compounding, and those questions move through the courts and the rulemaking process rather than through a patient alert.

What the update does signal is the FDA's continued attention to how weight-loss drugs are marketed and sold online, and a clearer, class-wide framing of the risks it wants patients to weigh. For telehealth companies, the red-flag list is effectively a public description of the practices the agency views as warning signs.

Practical notes for patients

This is general information, not medical advice. With that caveat, the steps the FDA points patients toward are straightforward:

• Obtain a prescription from a licensed clinician who evaluates you, and fill it at a state-licensed pharmacy.
• Be cautious with sellers matching the FDA's red-flag list, especially those claiming a compounded product is identical to the approved drug.
• Follow the storage and single-vial guidance, including refrigeration and the recommendation to discard a multi-dose vial within 28 days of first use.
• Talk to your own doctor or pharmacist with questions about a specific product or dose, and report suspected problems to the FDA's MedWatch program.